• Je něco špatně v tomto záznamu ?

Cognitive impairment associated with Hodgkin's lymphoma and chemotherapy

D. Fayette, V. Juríčková, T. Kozák, H. Mociková, L. Gaherová, I. Fajnerová, J. Horáček

. 2023 ; 797 (-) : 137082. [pub] 20230121

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004153

Chemotherapy-related cognitive impairment (CRCI) is a well-documented side effect of cancer treatment in various types of tumors including Hodgkin's lymphoma (HL). However, a longitudinal study evaluating the cognitive performance of HL patients has been completely lacking. The aim of the study was to determine the presence of CRCI in HL patients before, promptly after, and 6 months after treatment. Thirty-six patients newly diagnosed with HL and 45 healthy controls (HC) completed the neuropsychological battery and psychological measures of affective distress and quality of life. The results indicate that HL patients have impaired performance compared to HC which cannot be explained by emotional factors. Cognitive impairments prior to treatment were found in 3 of 6 cognitive domains, i.e., verbal memory and learning, speed of processing/psychomotor speed, and abstraction/executive function. Promptly after the chemotherapy, deficits were found in the domains of memory and learning, verbal memory, speed of processing/psychomotor speed, and abstraction/executive function. Weaker cognitive performance persist even 6 months after the end of chemotherapy, specifically in domains of verbal memory and learning, and abstraction/executive function. Our results indicate the presence of cognitive impairment in HL patients already prior to treatment and increased damages caused by chemotherapy, while some of them may last for up to 6 months after the treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004153
003      
CZ-PrNML
005      
20240807135702.0
007      
ta
008      
230418e20230121ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.neulet.2023.137082 $2 doi
035    __
$a (PubMed)36693557
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Fayette, Dan, $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic. Electronic address: danfayette@gmail.com $d 1981- $7 xx0321144
245    10
$a Cognitive impairment associated with Hodgkin's lymphoma and chemotherapy / $c D. Fayette, V. Juríčková, T. Kozák, H. Mociková, L. Gaherová, I. Fajnerová, J. Horáček
520    9_
$a Chemotherapy-related cognitive impairment (CRCI) is a well-documented side effect of cancer treatment in various types of tumors including Hodgkin's lymphoma (HL). However, a longitudinal study evaluating the cognitive performance of HL patients has been completely lacking. The aim of the study was to determine the presence of CRCI in HL patients before, promptly after, and 6 months after treatment. Thirty-six patients newly diagnosed with HL and 45 healthy controls (HC) completed the neuropsychological battery and psychological measures of affective distress and quality of life. The results indicate that HL patients have impaired performance compared to HC which cannot be explained by emotional factors. Cognitive impairments prior to treatment were found in 3 of 6 cognitive domains, i.e., verbal memory and learning, speed of processing/psychomotor speed, and abstraction/executive function. Promptly after the chemotherapy, deficits were found in the domains of memory and learning, verbal memory, speed of processing/psychomotor speed, and abstraction/executive function. Weaker cognitive performance persist even 6 months after the end of chemotherapy, specifically in domains of verbal memory and learning, and abstraction/executive function. Our results indicate the presence of cognitive impairment in HL patients already prior to treatment and increased damages caused by chemotherapy, while some of them may last for up to 6 months after the treatment.
650    _2
$a lidé $7 D006801
650    12
$a Hodgkinova nemoc $x komplikace $x farmakoterapie $7 D006689
650    _2
$a longitudinální studie $7 D008137
650    _2
$a kvalita života $7 D011788
650    12
$a kognitivní dysfunkce $x chemicky indukované $x komplikace $7 D060825
650    _2
$a exekutivní funkce $7 D056344
650    _2
$a neuropsychologické testy $7 D009483
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Juríčková, Veronika $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660/32, 121 08 Prague 2, Czech Republic. Electronic address: veronika.jurickova@nudz.cz
700    1_
$a Kozák, Tomáš $u Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic; University Hospital Královské Vinohrady, Šrobárova 50, 100 34, Prague 10, Czech Republic. Electronic address: tomas.kozak@fnkv.cz
700    1_
$a Mociková, Heidi $u Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic; University Hospital Královské Vinohrady, Šrobárova 50, 100 34, Prague 10, Czech Republic. Electronic address: heidi.mocikova@fnkv.cz
700    1_
$a Gaherová, Lubica $u Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic; University Hospital Královské Vinohrady, Šrobárova 50, 100 34, Prague 10, Czech Republic. Electronic address: lubica.gaherova@fnkv.cz
700    1_
$a Fajnerová, Iveta $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic. Electronic address: iveta.fajnerova@nudz.cz
700    1_
$a Horáček, Jiří $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic. Electronic address: jiri.horacek@nudz.cz
773    0_
$w MED00003507 $t Neuroscience letters $x 1872-7972 $g Roč. 797 (20230121), s. 137082
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36693557 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20240807135657 $b ABA008
999    __
$a ok $b bmc $g 1924674 $s 1190362
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 797 $c - $d 137082 $e 20230121 $i 1872-7972 $m Neuroscience letters $n Neurosci. lett. $x MED00003507
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace